Haleon heads into its July 30 results with a tidy 4.2% weekly gain and an almost complete absence of short-side pressure — a combination that leaves the setup looking calm rather than charged.
The lending market tells a story of near-total indifference from short sellers. Availability is essentially unlimited — over 5.3 billion shares remain available to borrow, far exceeding any plausible demand. Borrowing costs have eased around 11% on the week to just 0.51%, their lowest level in over a month. The short score sits at 29, flat across the past two weeks and well below the mid-January peak of around 35. For context, Haleon ranks in the 87th percentile on short score rank — meaning it is less shorted than the overwhelming majority of stocks in the universe. There is no sign of shorts building ahead of earnings.
The Street's view is mixed but tilts constructive. The consensus price target of 434p implies roughly 25% upside from the current 347.7p close, a gap wide enough to suggest the market has not yet bought the bull case in full. The most notable factor-score divergence is between the dividend signal and earnings surprise: Haleon ranks in the 94th percentile on dividend score, pointing to a reliable income profile, yet the EPS surprise score sits at just 9 — meaning the company has been among the weaker beat-and-raise names in its cohort. That tension between income reliability and earnings momentum consistency is the central debate. Valuation multiples are drifting modestly lower: the PE ratio has eased by roughly 0.6 points over the past 30 days to 15.6x, and EV/EBITDA has slipped to 11.9x. Neither is alarming, but the direction is gently southward.
Among the closest peers, AZN gained 3.8% on the week and GSK added 1.2%, making Haleon's 4.2% move look broadly in line with a pharma-positive week in London. Further afield, MRK surged 7.4% and BMY added 3.8%, suggesting the broader sector caught a bid. Haleon kept pace without leading the move.
The insider record is now stale — the most recent disclosed transaction was CEO Brian McNamara's award-and-sell in March, a routine vesting event that carried low significance scores. No new insider activity has emerged since, so that angle adds little to the current setup.
With Q2 results due July 30, the focus narrows to whether Haleon can begin closing the gap between its strong dividend credentials and a consistently underwhelming earnings-beat record — the distance between those two signals is what will most likely determine how the market receives the next print.
See the live data behind this article on ORTEX.
Open HLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
